Cardiovascular Outcomes of Vildagliptin in Patients with Type 2 Diabetes Mellitus after Acute Coronary Syndrome or Acute Ischemic Stroke

ConclusionsAmong patients with T2DM after a recent ACS or AIS, treatment with vildagliptin was not associated with increased risks of CV death, nonfatal MI, nonfatal stroke, and hospitalization for HF.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Original Article Source Type: research

Related Links:

Conclusion Activation of the Nrf2-dependent antioxidant system plays an important role in cell defense against oxidative stress damage, whereas the insufficiency of the Nrf2 system is associated with multiple aspects of the genesis and progression of metabolic diseases, posing a great risk to the cardiovascular system (Figure 1). The systemic increase of Nrf2 activity by several activators may be beneficial in the treatment of metabolic diseases. In addition, selective upregulation of Nrf2 genes may represent a potential therapy in obesity, diabetes and atherosclerosis. Looking to the future, experimental research that el...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: Patients with T2DM and prior MI are at high risk of MACE and CV death/HHF. Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients. Future studies should aim to confirm the large clinical benefits with SGLT2i we observed in patients with prior MI. CLINICAL TRIAL REGISTRATION: URL: Unique Identifier: NCT01730534. PMID: 30882239 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Publication date: Available online 29 September 2018Source: American Heart JournalAuthor(s): Aruna D. Pradhan, Nina P. Paynter, Brendan M. Everett, Robert J. Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R. Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G. Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M RidkerAbstractObservational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selec...
Source: American Heart Journal - Category: Cardiology Source Type: research
Conclusion The DECLARE–TIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV events. DECLARE–TIMI 58 is the largest study to address this question with an SGLT-2 inhibitor in patients with T2DM and with established CV disease and without CV disease but with multiple risk factors.
Source: American Heart Journal - Category: Cardiology Source Type: research
ConclusionsIn patients with diabetes and elevated CV risk, even after extensive adjustment for underlying disease burden, there was a persistent association for low DBP with subclinical myocardial injury and risk of MI.
Source: European Heart Journal - Category: Cardiology Source Type: research
This study aimed to evaluate whether the use of β-blockers is effective in patients with diabetes mellitus and whether its use is associated with the occurrence of severe hypoglycemia. Using the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes) data, we performed Cox proportional hazards analyses with a propensity score adjustment. The primary outcome was the first occurrence of a cardiovascular event during the study period, which included nonfatal myocardial infarction, unstable angina, nonfatal stroke, and cardiovascular death. The mean follow-up periods (±SD) were 4.6±1.6 years in pati...
Source: Hypertension - Category: Cardiology Authors: Tags: Cardiovascular Disease, Diabetes, Type 2, Chronic Ischemic Heart Disease, Heart Failure Original Articles Source Type: research
Conclusion: In diabetic patients with SIHD and previous MI, adding prompt revascularization to intensive medical therapy yielded no benefit compared with intensive medical therapy alone. These findings underscore the importance of intensive medical therapy in mitigating further ischemic events.
Source: Coronary Artery Disease - Category: Cardiology Tags: Original Research Source Type: research
Conclusions In this nationwide T2DM cohort, the risks of mortality and the combination of MI and ischaemic stroke were lower for patients receiving DPP-4 inhibitors than for those who did not receive such treatment. DPP-4 inhibitor use was not associated with a higher risk of hospitalisation for HF even in patients with pre-existing HF.
Source: Heart - Category: Cardiology Authors: Tags: Health policy, Drugs: cardiovascular system, Acute coronary syndromes, Epidemiology, Diabetes, Metabolic disorders Heart failure and cardiomyopathies Source Type: research
Conclusions—Pioglitazone reduces recurrent stroke and major vascular events in ischemic stroke patients with insulin resistance, prediabetes, and diabetes mellitus.
Source: Stroke - Category: Neurology Authors: Tags: Cardiovascular Disease, Diabetes, Type 2, Secondary Prevention, Meta Analysis, Cerebrovascular Disease/Stroke Original Contributions Source Type: research
More News: Cardiology | Cardiovascular | Chia | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Health Insurance | Heart | Heart Attack | Heart Failure | Insurance | Ischemic Stroke | Stroke | Taiwan Health